QurieGen
Private Company
Total funding raised: $2M
Overview
QurieGen is an early-stage biotechnology company pioneering a 'lab-in-the-loop' platform that integrates proprietary single-cell multi-omics data generation with AI-driven simulation. Its core technology, QuRIE-seq, simultaneously captures time-resolved transcriptomic and proteomic data from individual cells to quantify dynamic responses to perturbations. The company's primary business model is partnering with pharmaceutical and biotech firms, offering its platform and predictive models to de-risk and accelerate drug discovery in oncology and immunology. As a private, likely pre-revenue entity, QurieGen is positioning itself as a key enabler in the shift towards more predictive, biology-driven R&D.
Technology Platform
Integrated 'lab-in-the-loop' platform combining proprietary single-cell multi-omics technology (QuRIE-seq) for time-resolved transcriptomic and proteomic data with AI-powered virtual cell models for predictive simulation.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
QurieGen competes with single-cell multi-omics tool providers (e.g., 10x Genomics), AI-driven drug discovery companies (e.g., Recursion, Exscientia), and CROs offering advanced analytics. Its key differentiator is the integrated generation of proprietary, temporal, multi-omic data (RNA+protein) specifically for AI model training within a closed-loop platform.